查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086195

非侵入性產前檢測市場：依檢測類型、技術、懷孕週數、交付方式及最終用戶分類－2026-2032年全球市場預測

Non-invasive Prenatal Testing Market by Test Type, By Technology, Gestation Period, Mode of Delivery, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非侵入性產前檢測市場將成長至 119.5 億美元，複合年成長率為 8.10%。

主要市場統計數據
基準年 2025 69.3億美元
預計年份：2026年 73.6億美元
預測年份 2032 119.5億美元
複合年成長率 (%) 8.10%

非侵入性產前檢測（NIPT）可在懷孕初期分析母體血液樣本中的遊離細胞DNA（cfDNA），已從高風險懷孕的輔助手段發展成為主流的產前篩檢方法。該領域最成熟的篩檢是21三體症、18三體症和13三體症。專家指南強調，如果篩檢結果呈陽性，則必須透過絨毛膜取樣或羊膜穿刺術進行確診。

市場成長動能主要受以下因素驅動：許多國家孕婦年齡成長、臨床醫生認知度提高、私人和公共保險報銷管道擴大，以及次世代定序和生物資訊技術的持續進步。從搜尋引擎最佳化和商業性定位的角度來看，搜尋量最高的關鍵字仍然是「非侵入性產前檢測」、「NIPT市場」、「產前基因篩檢」、「cfDNA檢測」、「三體症候群篩檢」、「胎兒非整倍體篩檢」和「生殖健康檢查」。

NIPT領域發生的變革性變化

非侵入性產前檢測（NIPT）的格局正在重塑，其模式正從基於風險的篩檢轉向更普及的產前篩檢。儘管包括美國婦產科醫師學會（ACOG）和母胎醫學會（SMFM）在內的醫療機構倡導為所有孕婦提供產前基因篩檢，但許多醫療系統仍沿用基於臨床風險、成本效益、保險報銷政策和檢查室能力等本地標準。

人工智慧在非侵入性產前檢測中的累積影響

在非侵入性產前檢測（NIPT）工作流程中，人工智慧（AI）的應用正從自由應用轉變為累積。機器學習模型正被用於定序品管、胎兒來源評估、非整倍體訊號檢測、檢體選擇、突變解讀輔助以及提升檢查室自動化程度。這些工具減少了人工審核，加快了報告速度，並使檢查室能夠在不影響分析一致性的前提下處理更多檢測。

全球NIPT應用的關鍵區域性見解

北美地區憑藉其先進的臨床應用、完善的檢查室基礎設施以及鼓勵為所有孕婦提供產前篩檢的指南，仍然是無創產前檢測（NIPT）市場的領先地區。美國受益於大規模的參考檢查室網路、母胎醫學專業知識以及保險公司主導的主導審查，而加拿大各省在公共資金和報銷標準方面存在差異。

針對特定群體的NIPT市場策略的關鍵洞察

在東協市場，隨著都市區私立醫院和專科婦產中心將非侵入性產前檢測（NIPT）納入高品質產前護理，NIPT 的應用正在擴大。然而，由於收入水準、報銷機制和地區等因素，NIPT 的可及性仍存在差異。在海灣合作理事會（GCC）國家，由於國家醫療衛生現代化、三級醫療機構的擴建、醫療旅遊以及對基因組研究的投資，NIPT 市場正在擴張，其需求主要集中在醫院網路內的重症患者以及自費醫療機構。

各國對NIPT成長優先事項的關鍵見解。

美國在商業化非侵入性產前檢測 (NIPT) 的規模、保險公司政策的演變以及檢查室自建檢測 (LDT) 的基礎設施方面均處於主導。在加拿大，NIPT 的普及受到各省篩檢計畫和地區特定合格標準的影響。墨西哥和巴西是拉丁美洲的重要市場，私立醫院、專科診所和參考實驗室推動了 NIPT 的普及，同時，產科醫生對 NIPT 的認知不斷提高，以及都市區對先進產前基因篩檢的需求日益成長，也促進了 NIPT 的普及。

為NIPT產業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的檢測組合、透明的績效報告和整合的遺傳諮詢。當檢測實驗室清楚傳達疾病特異性陽性預測值 (PPV)、解釋篩檢的局限性、揭露胎兒來源率和處理商業性結果的政策，並建立轉診途徑時，商業成長才能得到最有效的促進。

NIPT市場情報調查方法

本NIPT市場情報基於一套系統化的調查方法，該方法結合了二次調查、一次檢驗和資料三角測量。資訊來源包括同行評審的臨床文獻、專業學會指南、監管資料庫、公共保險報銷政策、專利和產品映射、實驗室認證參考資料以及國家級健康指標。

結論：NIPT市場的策略展望

NIPT（非侵入性產前檢測）如今已成為現代產前基因篩檢的核心組成部分，這得益於cfDNA科學、定序技術、人工智慧分析以及不斷完善的臨床指南的進步。儘管市場正從早期應用階段朝著更廣泛應用階段發展，但其進展仍取決於保險報銷、諮詢系統、監管合規、資料保護以及公平實施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 非侵入性產前檢測市場：依檢測類型分類

  • 染色體數目異常篩檢
    • 13號染色體三體症候群（帕陶氏症候群）
    • 18號染色體三體綜合症（愛德華氏症候群）
    • 21三體症（唐氏症）
  • 微缺失症候群
    • 1p36 缺失
    • 22q11.2缺失（迪喬治症候群）
    • 尖叫症候群
  • 性染色體非整倍體（SCA）
    • 柯林菲特氏症（XXY）
    • 三X症候群（XXX）
    • 透納氏症（X染色體單染色單體症候群）
    • XYY綜合症
  • 全基因組篩檢

第8章 非侵入性產前檢測市場：依技術分類

  • 利用微陣列進行分析
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 滾動循環放大器（RCA）

第9章 非侵入性產前檢測市場：依懷孕階段分類

  • 10-17週
  • 18-23週
  • 23週或以上

第10章 非侵入性產前檢測市場：以交付方式分類

  • 家庭檢體收集
  • 檢查室檢測服務
  • 即時檢測

第11章 非侵入性產前檢測市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 專科診所

第12章 非侵入性產前檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 非侵入性產前檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非侵入性產前檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Agilent Technologies, Inc.
  • BGI Group
  • BillionToOne, Inc.
  • Biora Therapeutics, Inc.
  • BioReference Laboratories, Inc.
  • Centogene NV
  • Eurofins Scientific SE
  • F.Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Igenomix SLU by Vitrolife Group
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lilac Insights Pvt. Ltd.
  • MedGenome Labs Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Ravgen Inc.
  • Sonic Healthcare USA
  • Thermo Fisher Scientific Inc.
  • Yourgene Health by Novacyt UK Holdings Limited
Product Code: MRR-036C5CF3B521

The Non-invasive Prenatal Testing Market is projected to grow by USD 11.95 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.93 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.95 billion
CAGR (%) 8.10%

Non-invasive prenatal testing (NIPT) has moved from a high-risk pregnancy adjunct to a mainstream prenatal screening option because it analyzes cell-free DNA (cfDNA) from a maternal blood sample as early as the first trimester. The category is most strongly established for trisomy 21, trisomy 18, and trisomy 13 screening, with professional guidance emphasizing that positive screening results require confirmatory diagnostic testing through chorionic villus sampling or amniocentesis.

Market momentum is supported by rising maternal age in many countries, broader clinician awareness, expanding private and public reimbursement pathways, and continuous improvements in next-generation sequencing and bioinformatics. For SEO and commercial positioning, the highest-intent themes remain non-invasive prenatal testing, NIPT market, prenatal genetic screening, cfDNA testing, trisomy screening, fetal aneuploidy screening, and reproductive health diagnostics.

Transformative Shifts in the NIPT Landscape

The NIPT landscape is being reshaped by a clear shift from risk-based access toward more universal prenatal screening models. Medical societies, including ACOG and SMFM, support offering prenatal genetic screening options to all pregnant patients, while many health systems still apply local criteria based on clinical risk, cost-effectiveness, reimbursement policy, and laboratory capacity.

The second major shift is the expansion of test menus beyond common autosomal trisomies. Laboratories are adding sex chromosome aneuploidies, selected microdeletions, genome-wide copy-number signals, RhD status assessment in selected settings, and twin pregnancy applications, although clinical utility, counseling needs, and positive predictive value vary by indication. Competitive differentiation increasingly depends on transparent validation, fetal fraction management, turnaround time, genetic counseling support, data security, and reimbursement evidence.

Cumulative Impact of Artificial Intelligence on NIPT

Artificial intelligence is becoming cumulative rather than isolated in NIPT workflows. Machine learning models are used to improve sequencing quality control, fetal fraction estimation, aneuploidy signal detection, sample triage, variant interpretation support, and laboratory automation. These tools can reduce manual review, support faster reporting, and help laboratories manage higher test volumes without compromising analytical consistency.

The strategic value of AI is strongest when models are validated across diverse maternal ages, gestational ages, body mass index ranges, ethnic backgrounds, and pregnancy types. Because NIPT is a screening test with medical and ethical implications, AI-enabled claims must remain auditable, explainable, and aligned with CLIA, CAP, ISO 15189, HIPAA, GDPR, EU IVDR, and local data protection requirements.

Key Regional Insights Across Global NIPT Adoption

North America remains a leading NIPT market due to advanced clinical adoption, strong laboratory infrastructure, and guidance that supports offering prenatal screening options to all pregnant patients. The United States benefits from large reference laboratory networks, maternal-fetal medicine specialization, and payer-driven evidence reviews, while Canada reflects province-level variability in publicly funded access and reimbursement criteria.

Europe is defined by structured public health pathways, national reimbursement decisions, and the tightening compliance environment under the EU In Vitro Diagnostic Regulation. Asia-Pacific is a major adoption opportunity by birth volume and healthcare investment, with China, India, Japan, South Korea, and Australia showing different combinations of scale, regulation, clinical acceptance, and private-sector diagnostic access. Latin America is advancing through private-sector adoption in Brazil and Mexico, supported by expanding obstetric awareness and reference laboratory availability. The Middle East is supported by GCC investment in tertiary care, medical genetics, and genomics programs, while Africa remains underpenetrated, with growth constrained by affordability, laboratory capacity, sample logistics, and referral infrastructure.

Key Group Insights for NIPT Market Strategy

ASEAN markets are expanding as urban private hospitals and specialist maternity centers add NIPT to premium prenatal care, although access remains uneven across income groups, reimbursement systems, and geographies. The GCC is advancing through national healthcare modernization, tertiary hospital expansion, medical tourism, and genomics investment, with demand concentrated in high-acuity hospital networks and privately funded care pathways.

The European Union is shaped by public reimbursement assessments, health technology evaluation, GDPR, and EU IVDR compliance, making clinical evidence and data governance central to adoption. BRICS countries create a scale-driven opportunity because China, India, and Brazil combine high birth volumes with growing private diagnostics networks, while Russia and South Africa present more fragmented access and infrastructure variability. G7 markets set clinical evidence, reimbursement, and regulatory benchmarks for prenatal genetic screening, and NATO countries largely overlap with high-income health systems where regulatory quality, cybersecurity, and resilient diagnostic supply chains influence procurement and laboratory partnerships.

Key Country Insights for NIPT Growth Prioritization

The United States leads in commercial NIPT scale, payer policy evolution, and laboratory-developed testing infrastructure, while Canada shows adoption shaped by provincial screening programs and region-specific eligibility policies. Mexico and Brazil are important Latin American markets where private hospitals, specialty clinics, and reference laboratories drive uptake, supported by rising awareness among obstetricians and higher demand for advanced prenatal genetic screening in urban centers.

In Europe, the United Kingdom uses structured NHS pathways, Germany covers NIPT in defined medical situations, and France supports reimbursed access through established prenatal screening processes. Italy and Spain show regional implementation differences, and Russia is more reliant on private diagnostics and urban referral centers. In Asia-Pacific, China offers unmatched scale and growing domestic genomics capacity, India requires strict compliance with sex-selection laws under prenatal diagnostic regulations, Japan emphasizes authorized clinical settings and careful genetic counseling, Australia has strong specialist adoption and private access pathways, and South Korea combines advanced digital health infrastructure with high maternal care standards and sophisticated laboratory capability.

Actionable Recommendations for NIPT Industry Leaders

Industry leaders should prioritize clinically validated test portfolios, transparent performance reporting, and genetic counseling integration. Commercial growth is strongest when laboratories communicate positive predictive value by condition, explain screening limitations, disclose fetal fraction and no-call handling policies, and build referral pathways for confirmatory diagnostic testing.

Executives should also invest in reimbursement evidence, local regulatory compliance, privacy-by-design data systems, and interoperable digital ordering and reporting. Partnerships with obstetric networks, maternal-fetal medicine specialists, payers, and public health programs can reduce adoption barriers. In emerging markets, tiered pricing, regional sample logistics, local physician education, and culturally appropriate patient communication are essential for sustainable NIPT expansion.

Research Methodology for NIPT Market Intelligence

A structured methodology combining secondary research, primary validation, and data triangulation supports this NIPT market intelligence. Sources include peer-reviewed clinical literature, professional society guidance, regulatory databases, public reimbursement policies, patent and product mapping, laboratory accreditation references, and country-level healthcare indicators.

Primary inputs are validated through interviews and expert review across diagnostic laboratories, obstetric care providers, payers, distributors, and regulatory specialists. Findings are normalized by test type, application, end user, region, and country to identify adoption drivers, constraints, and competitive positioning. Only evidence-supported claims are retained for executive interpretation, with explicit exclusion of unsupported estimates, market sizing, market share, or forecasting statements.

Conclusion: Strategic Outlook for the NIPT Market

NIPT is now a core component of modern prenatal genetic screening, supported by advances in cfDNA science, sequencing technology, AI-enabled analytics, and expanding clinical guidance. The market is evolving from early adoption toward broader access, but progress remains dependent on reimbursement, counseling capacity, regulatory compliance, data protection, and equitable implementation.

Organizations that combine scientific rigor with scalable operations will be best positioned to win. The strongest opportunities lie in validated menu expansion, regional access strategies, AI-supported workflow efficiency, robust quality management, and trusted partnerships across obstetric care, laboratory medicine, payers, and public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-invasive Prenatal Testing Market, by Test Type

  • 7.1. Aneuploidy Screening
    • 7.1.1. Trisomy 13 (Patau Syndrome)
    • 7.1.2. Trisomy 18 (Edwards Syndrome)
    • 7.1.3. Trisomy 21 (Down Syndrome)
  • 7.2. Microdeletion Syndromes
    • 7.2.1. 1p36 Deletion
    • 7.2.2. 22q11.2 Deletion (DiGeorge Syndrome)
    • 7.2.3. Cri-du-chat Syndrome
  • 7.3. Sex Chromosome Aneuploidies (SCA)
    • 7.3.1. Klinefelter Syndrome (XXY)
    • 7.3.2. Triple X Syndrome (XXX)
    • 7.3.3. Turner Syndrome (Monosomy X)
    • 7.3.4. XYY Syndrome
  • 7.4. Whole-Genome Screening

8. Non-invasive Prenatal Testing Market, by By Technology

  • 8.1. Microarray-Based Analysis
  • 8.2. Next-Generation Sequencing (NGS)
  • 8.3. Polymerase Chain Reaction (PCR)
  • 8.4. Rolling Circle Amplification (RCA)

9. Non-invasive Prenatal Testing Market, by Gestation Period

  • 9.1. 10-17 Week
  • 9.2. 18-23 Week
  • 9.3. Above 23 Week

10. Non-invasive Prenatal Testing Market, by Mode of Delivery

  • 10.1. At-Home Sample Collection
  • 10.2. Laboratory-Based Testing Services
  • 10.3. Point-of-Care Testing

11. Non-invasive Prenatal Testing Market, by End-User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Non-invasive Prenatal Testing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Non-invasive Prenatal Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-invasive Prenatal Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Agilent Technologies, Inc.
  • 16.2. BGI Group
  • 16.3. BillionToOne, Inc.
  • 16.4. Biora Therapeutics, Inc.
  • 16.5. BioReference Laboratories, Inc.
  • 16.6. Centogene N.V.
  • 16.7. Eurofins Scientific SE
  • 16.8. F.Hoffmann-La Roche Ltd.
  • 16.9. GE HealthCare Technologies Inc.
  • 16.10. Igenomix S.L.U by Vitrolife Group
  • 16.11. Illumina, Inc.
  • 16.12. Labcorp Holdings Inc.
  • 16.13. Laboratory Corporation of America Holdings
  • 16.14. Lilac Insights Pvt. Ltd.
  • 16.15. MedGenome Labs Ltd.
  • 16.16. Myriad Genetics, Inc.
  • 16.17. Natera, Inc.
  • 16.18. Quest Diagnostics Incorporated
  • 16.19. Ravgen Inc.
  • 16.20. Sonic Healthcare USA
  • 16.21. Thermo Fisher Scientific Inc.
  • 16.22. Yourgene Health by Novacyt UK Holdings Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANEUPLOIDY SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRISOMY 13 (PATAU SYNDROME) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRISOMY 13 (PATAU SYNDROME) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRISOMY 13 (PATAU SYNDROME) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRISOMY 18 (EDWARDS SYNDROME) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRISOMY 18 (EDWARDS SYNDROME) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRISOMY 18 (EDWARDS SYNDROME) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRISOMY 21 (DOWN SYNDROME) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRISOMY 21 (DOWN SYNDROME) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRISOMY 21 (DOWN SYNDROME) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICRODELETION SYNDROMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICRODELETION SYNDROMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICRODELETION SYNDROMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 1P36 DELETION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL 1P36 DELETION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 1P36 DELETION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 22Q11.2 DELETION (DIGEORGE SYNDROME) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 22Q11.2 DELETION (DIGEORGE SYNDROME) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 22Q11.2 DELETION (DIGEORGE SYNDROME) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRI-DU-CHAT SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRI-DU-CHAT SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRI-DU-CHAT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEX CHROMOSOME ANEUPLOIDIES (SCA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEX CHROMOSOME ANEUPLOIDIES (SCA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEX CHROMOSOME ANEUPLOIDIES (SCA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KLINEFELTER SYNDROME (XXY) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KLINEFELTER SYNDROME (XXY) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KLINEFELTER SYNDROME (XXY) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRIPLE X SYNDROME (XXX) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRIPLE X SYNDROME (XXX) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRIPLE X SYNDROME (XXX) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TURNER SYNDROME (MONOSOMY X) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TURNER SYNDROME (MONOSOMY X) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TURNER SYNDROME (MONOSOMY X) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL XYY SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL XYY SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL XYY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL WHOLE-GENOME SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL WHOLE-GENOME SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WHOLE-GENOME SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICROARRAY-BASED ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICROARRAY-BASED ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICROARRAY-BASED ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ROLLING CIRCLE AMPLIFICATION (RCA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ROLLING CIRCLE AMPLIFICATION (RCA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ROLLING CIRCLE AMPLIFICATION (RCA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL 10-17 WEEK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL 10-17 WEEK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL 10-17 WEEK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL 18-23 WEEK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 18-23 WEEK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 18-23 WEEK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ABOVE 23 WEEK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ABOVE 23 WEEK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ABOVE 23 WEEK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AT-HOME SAMPLE COLLECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AT-HOME SAMPLE COLLECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AT-HOME SAMPLE COLLECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LABORATORY-BASED TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LABORATORY-BASED TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LABORATORY-BASED TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 156. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 157. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 158. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 160. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 176. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 183. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 184. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 185. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 187. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 192. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 194. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 196. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 213. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 276. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 294. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 303. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY